01 December 2008
Biomarkers of hypercoagulability and inflammation in primary hyperparathyroidism
Elena Chertok-ShachamE, Avraham IshayDF, Idit LaviC, Rafael LuboshitzkyADEFGMed Sci Monit 2008; 14(12): CR628-632 :: ID: 869485
Abstract
Background
Severe primary hyperparathyroidism (PHP) has been associated with increased cardiovascular morbidity. Hypertension, dyslipidemia and impaired glucose metabolism were demonstrated in severe PHP, with improvement after surgery in these variables. Such an association in mild PHP is not known. The study was conducted to determine biomarkers of hypercoagulability and inflammation for cardiovascular disease in patients with primary hyperparathyroidism.
Material and Method
Patients (n=35) without CVD were evaluated. Patients were subdivided into two groups, severe (n=15) and mild (n=20) hyperparathyroidism, based on disease severity and whether they had indications for surgery. Results were compared with those obtained in 25, age and weight matched controls. Participants were examined in the hospital endocrine clinic and had measurement of fasting blood levels of calcium, phosphate, alkaline phosphatase, PTH, C-reactive protein, Serum IL-6, D-dimers, Fibrinogen, plasminogen activator inhibitor 1 [PAI-1], and white blood cells (WBC) count.
Results
PAI-1 was significantly higher in symptomatic patients (41.4 g/L +/-20) vs. controls (32.5 g/L +/-13.0); (p=0.009). Levels of fibrinogen, d-dimers, IL-6, CRP and leukocytes were similar in patients and controls. Across all subjects PAI-1 was significantly correlated with PTH levels (f=8.44;p=0.005).
Conclusions
Patients with severe primary hyperparathyroidism have increased risk for cardiovascular disease, mainly due to the effect of PTH and also the duration and severity of disease. Elevated PAI-1 levels may imply that hypercoagulability may be involved in the pathogenesis of CVD in these patients.
Keywords: Hyperparathyroidism, Primary - physiopathology, Case-Control Studies, Biological Markers - blood
Editorial
01 July 2026 : Editorial
Editorial: The WHO Identifies Ebola Disease Due to Bundibugyo Virus as a Public Health Emergency of International Concern (PHEIC) as Vaccine Development AcceleratesDOI: 10.12659/MSM.954627
Med Sci Monit 2026; 32:e954627
In Press
Clinical Research
Nasopharyngeal Carriage of Neisseria meningitidis in 181 Hajj and Umrah Pilgrims in Türkiye: Pre- and Post-...Med Sci Monit In Press; DOI: 10.12659/MSM.952640
Review article
The Roles of Gut Microbiota in the Pathogenesis of Acute PancreatitisMed Sci Monit In Press; DOI: 10.12659/MSM.952647
Meta-Analysis
Effectiveness of Cardiac Telerehabilitation in Improving Functional Capacity, Quality Of Life and Cardiovas...Med Sci Monit In Press; DOI: 10.12659/MSM.953366
Clinical Research
Analysis of the Clinical Characteristics and Endoscopic Features of Phytobezoar-Induced Ulcers and Gastric ...Med Sci Monit In Press; DOI: 10.12659/MSM.952191
Most Viewed Current Articles
17 Jan 2024 : Review article 14,176,425
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
13 Nov 2021 : Clinical Research 3,759,279
Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...DOI :10.12659/MSM.932788
Med Sci Monit 2021; 27:e932788
14 Dec 2022 : Clinical Research 2,466,239
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research 708,884
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387






